EGFR and cancer: Hence, CWI1-2, by targeting the endogenous IGF2BP2/EGFR/PI3K/AKT axis, represents a novel therapeutic approach that overcomes EGFR-targeted resistance attributed to both autonomous and non-cell-autonomous interactions between cancer cells and CAFs.